Last reviewed · How we verify

CTAP101 Injection — Competitive Intelligence Brief

CTAP101 Injection (CTAP101 Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: C1-esterase inhibitor (C1-INH) replacement therapy. Area: Immunology / Rare Genetic Disorders.

phase 3 C1-esterase inhibitor (C1-INH) replacement therapy C1-esterase inhibitor (C1-INH); complement and contact system regulation Immunology / Rare Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

CTAP101 Injection (CTAP101 Injection) — OPKO IP Holdings II, Inc.. CTAP101 is a recombinant human C1-esterase inhibitor (C1-INH) that regulates complement and contact system activation to prevent hereditary angioedema attacks.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CTAP101 Injection TARGET CTAP101 Injection OPKO IP Holdings II, Inc. phase 3 C1-esterase inhibitor (C1-INH) replacement therapy C1-esterase inhibitor (C1-INH); complement and contact system regulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (C1-esterase inhibitor (C1-INH) replacement therapy class)

  1. OPKO IP Holdings II, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CTAP101 Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/ctap101-injection. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: